BASEL, Switzerland (
, the Swiss pharmaceutical company, said third-quarter core earnings rose 17% to $3.15 billion on the strength of new products.
A year earlier, Novartis earned $2.68 billion.
Sales in the quarter rose to 13% to $12.58 billion, with recently launched products contributing 20%, or $2.3 billion, to net sales.
Novartis said Thursday that acquisitions contributed 6 percentage points to growth, mainly driven by Alcon's sales of $617 million. Novartis completed the acquisition of Alcon, the eye care company, in the third quarter.
Novartis said for the full year, group sales, which will include four months of Alcon, are expected in constant currencies to grow in the low- to mid-teens.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to: